Abstract Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes.
Introduction
The mammalian genome encodes more than 500 protein kinases which mainly phosphorylate serine, threonine and tyrosine residues in substrate proteins [1, 2] . These kinases are important regulators of nearly all cellular processes. Apart from controlling normal cellular processes, many kinases are also overexpressed or mutated in cancers. Thus, kinases are valuable drug targets for the treatment of cancers. The protein kinase C (PKC) family of protein serine/ threonine kinases was initially described in 1977 as a cyclic nucleotide-independent kinase [3] . Gradually, this family became a multi-gene family of ten protein serine/threonine kinases encoded by nine genes [4] , which are shown to be important intermediate regulators of many signaling cascades [5, 6] . Due to the varying tissue distribution as well as subcellular localization, PKC family proteins regulate diverse cellular processes and have been proven to be attractive drug targets in many cancers.
Chronic lymphocytic leukemia (CLL) accounts for 30 % of all leukemia and is the most common type of adult hematological malignancy in the Western world. CLL is a neoplastic disease characterized by the accumulation of small B lymphocytes with a mature appearance in bone marrow, blood, lymph nodes or other lymphoid tissues. Although initially CLL was thought to be a homogeneous disease, based on clinical and biological characteristics, this disease shows a high degree of heterogeneity (for a review see [7] ). Thus, treatment for CLL is apparently complicated, and survival varies from month to decades. For example, expression of ZAP-70 are associated with poor prognosis, and mutations in the tumor suppressor genes p53 and ATM are markers of aggressive disease with a phenotype resistant to conventional chemotherapy [7] . Therefore, invention of novel therapeutic agents will be highly beneficial for these groups of CLL patients.
The structure and classification of PKC isoforms
Protein kinase C isoforms are broadly subdivided into three subfamilies based on their domain structure and cofactor requirement [4] . The general structure of PKC proteins includes an amino-terminal regulatory domain and a carboxy-terminal catalytic domain. These two domains are composed of several conserved and variable regions (Fig. 1) . The classical or conventional PKC isoforms include PKCa, PKCbII and its splice variant PKCbI and PKCc. These four isoforms share equivalent domain structure including C1 and C2 domains in the regulatory part and a catalytic domain divided into two subdomains [8] . Two C1 domains are referred to as C1A and C1B which mediate association of phospholipids or diacylglycerol (DAG). The C2 domain is capable of interaction with two calcium ions. Thus, classical PKC isoforms are regulated by lipids and calcium ions. The two subdomains in the catalytic domain are so-called C3 and C4 domains [8] . While the C3 domain creates a cavity for ATP binding, C4 mainly act as substrate binding site. Novel PKC isoforms include PKCd, PKCe, PKCg and PKCh. These PKC isoforms also have C1A and C1B domains, while they lack a functional C2 domain. They are thus regulated by phospholipids and DAG but not by calcium ions. Instead of a functional C2 domain, the novel PKC isoforms contain a novel C2 domain that has important roles in cell signaling despite lacking affinity for calcium ions [9] . Atypical PKC isoforms, PKCf and PKCi, completely lack C2 domain and one C1 domain and are therefore independent of DAG and calcium for their regulation, but can be regulated by phospholipids. Atypical PKC isoforms contain a PB1 domain that plays a role in protein dimerization. Binding of DAG and calcium to the regulatory domain helps specific PKC isoforms to localize to the specific subcellular compartments. A common feature of all PKC isoforms is the presence of a pseudo-substrate (PS) region in the regulatory domain that occupies the substrate binding site and thereby keeps the enzyme in an inactive state [4] . Binding of factors to the regulatory domain causes necessary structural changes allowing PS to release the substrate binding site. These steps make PKC active and allow substrates to interact with the enzyme. Furthermore, association with factors can influence subcellular localization of PKC isoforms and thus PKC changes their subcellular localization upon activation.
Subcellular localization of PKC isoforms
The subcellular localization of PKC isoforms has been studied extensively [10] [11] [12] [13] [14] [15] . All PKC isoforms are expressed and retained in the cytosol before binding to their regulatory factors. Binding to DAG, or its analogs, and calcium ions increases membrane localization of the classical PKC isoforms [10, 11] . Novel PKC isoforms also display similar membrane localization in response to DAG analogs, while some of them are also localized to the cytosolic organelles [11] . Membrane translocation of PKC isoforms is required for PKC activation and further regulation of downstream signaling pathways. Although the DAG analog TPA is categorized as a potent tumor promoter, a macro-cyclic lactone bryostatin 1 (a mimic of TPA) can activate PKC by binding to the C1 domain, but does not induce differentiation of HL-60 cells and is also not a complete tumor promoter [12] . Thus, activation of PKC might have differential functions depending on associating molecules. Differential subcellular localization might also play a role in this process. The same factors can direct different PKC isoforms to the different cellular compartments. Bryostatin 1 treatment leads to translocation of PKCa from the cytosol to the plasma membrane, while it leads to translocation of PKCbII to the plasma membrane as well as to the nuclear membrane in the HL60 cell line [12] . In contrast, 4b-phorbol 12, 13-dibutyrate treatment induces complete translocation of PKCa to the plasma membrane, but only partial translocation of PKCbII to the same cellular compartment. Besides their translocation to the cell membrane, PKC isoforms have also been shown to be associated with other intracellular compartments. Many of them reside at the nuclear membrane or anchor with Golgi and mitochondrial membranes [16] . Thus, subcellular localization of PKC isoforms is directed by factor binding to the specific PKC isoforms and probably 
PKC isoforms and cancer
Although the tumor promoting properties of phorbol esters have been known for many years, the mechanism behind its activity remained a mystery before identification of PKC as a receptor of phorbol esters. Later many investigators established the complex roles of this family proteins in cancers [17] . PKC isoforms are mainly associated with activation of survival pathways leading to increased proliferation and survival. The classical PKCa and novel PKCe are the most potent activators of cell survival. While other PKC isoforms are also to some extent involved in oncogenicity, PKCd was described as both an oncogene and a tumor suppressor dependent of its tissue distribution. Although a majority of the studies established PKCa as an oncogene, its role in cancer is complex. PKCa triggers apoptosis in glioma cells [18] and inhibits growth of pancreatic cancer cells [19] . In addition, loss of PKCa expression potentiates cell proliferation in CaCo-2 cells [20] . One recent report suggests that PKCa expression is downregulated in CLL, colon cancer and glioblastoma [21] which is in line with previous observations that PKCa acts as a tumor suppressor in certain cancers. The expression levels of other PKC isoforms also differ between cancer types (Fig. 2) . Elevated PKCb expression was observed in B-cell lymphoma, while expression was lost in a melanoma cell line (for review see [22] ). PKCbII is also involved in enhancement of B-cell receptor (BCR) signaling in ZAP-70 expressing CLL cells [23] . Even though PKCd acts as a tumor suppressor in many cancers, it plays the opposite role in CLL. Inhibition of PKCd induces apoptosis in B-CLL cells [24] .
Although mutations in PKC isoforms are very rare, some earlier reports described certain types of mutations in different PKC isoforms. The D294G mutation in PKCa is the most studied mutation and was initially identified in a subpopulation of pituitary tumors [25] . Later this mutation was also observed in thyroid and breast cancers [26, 27] . Patients carrying PKCa-D294G mutation is linked to poor prognosis. The D294G mutation is a loss of function mutation [28] , and thus, PKCa acts as a tumor suppressor in these tumors. The tumor suppressor role of PKC isoforms has also been described in cancer, where treatment with ingenol mebutate (also called ingenol angelate or PEP005), an activator of a broad range of PKC isoforms, is effective against skin cancer and leukemia [29] [30] [31] . These observations suggest that different PKC isoforms play differential roles dependent on the cancer type.
Signaling from hematopoietic growth factor receptors
Growth factors mediate their biological effects through binding to the cell surface receptors. Binding of specific growth factor to the specific cell surface receptor activates downstream signaling resulting in cell proliferation and sometimes differentiation. Signals from growth factor are transduced by a number of intermediate signaling proteins including adaptors, scaffold proteins, non-receptor kinases and phosphatases [32] [33] [34] [35] [36] [37] [38] . Activation of PKC isoforms occurs in response to growth factors under physiological conditions. This process is partially mediated through growth factor-mediated phospholipase C (PLC) activation which by generating DAG and inositol trisphosphate (IP 3 ) from membrane phospholipids in turn activates classical and novel PKC isoforms. A variety of hematopoietic receptor tyrosine kinases signal through PKC isoforms as well. Binding of growth factors to these receptors leads to dimerization and auto-phosphorylation of the receptors on tyrosine residues which further creates docking sites for a number of signaling molecules [32] [33] [34] [35] [36] [37] . PKC isoforms amplify signals from these receptor by phosphorylating downstream substrates, while phosphatases counteract these processes [39] .
The role of type III receptor tyrosine kinases in hematopoietic malignancies has been extensively investigated. This group includes PDGFRa, PDGFRb, FLT3, KIT and M-CSFR (CSF1R). The ligand for platelet-derived growth factor receptor (PDGFR), PDGF, was originally purified from platelet extracts. Following injury, PDGF is released by monocytes and platelets. Although PDGFR plays a role in wound healing, its main role is in embryonal development. PDGF induces PKC activation through activation of phospholipase C (PLC), in particular PLCc1 [40] . Activation of PKC by PDGF results in induction of c-Fos promoter which subsequently enhances gene expression [41] . Furthermore, PKCa is involved in PDGF-induced DNA-synthesis [42] . PDGF stimulation induced nuclear translocation of PKCa [43] and nuclear localization of PKCd [44] . Thus, PDGF is able to regulate the subcellular localization of PKC isoforms, and PDGF-mediated biological effects are partially mediated through PKC isoforms. The stem cell factor (SCF) serves as a ligand for the c-Kit receptor. Both SCF and c-Kit are crucial regulators of early hematopoiesis. SCF stimulation activates PKC isoforms independent of PLC activity. Activated PKC then act as negative feedback loop in c-Kit signaling. PKC directly phosphorylates c-Kit receptor on multiple serine residues resulting in partial inhibition of SCF signaling [45] . Although SCF is practically unable to activate PLC, it can activate phospholipase D (PLD), which leads to release of phosphatidic acid that can further be dephosphorylated to generate DAG [46] . M-CSF-induced NF-jB activation can be blocked by specific PKC inhibitors or siRNA-mediated depletion of PKCa in monocytes [47] . M-CSF-mediated Erk activation and cell proliferation were also found to be dependent on PKC activation [48] . Another hematopoietic growth factor receptor, FLT3, is a frequently mutated gene in hematopoietic malignancies [49] . FLT3 is capable of activating PLCc [50, 51] suggesting that FLT3 can activate PKC isoforms. Furthermore, the PKC activator TPA activates Akt independent of PI3K in B-CLL, and using a specific PKCb inhibitor, TPA-induced Akt phosphorylation could be inhibited [52] . These findings suggest that hematopoietic growth factors can activate PKC isoforms through either PLC or PLD (Fig. 3) .
PKC expression in CLL
Protein kinase C isoforms display differential expression in various cancers. Since overexpression of PKC isoforms plays a role in cancer and since PKC is rarely mutated in cancers, it is important to know PKC expression profile in CLL before attempting to use this family of proteins as a target of intervention. Although an early study demonstrated lower total PKC activity in CLL as well as in three other hematopoietic disorders, a higher PKCb expression was found in CLL patients compared to PKCa and PKCc [53] . A more recent study investigated a more complete profile of PKC isoform expression. While all CLL patient samples analyzed displayed a significant level of PKCb, PKCc, PKCd and PKCf protein expression, the protein expression of PKCa, PKCe, PKCh and PKCi was found to vary from 0 to 67 % [54] . Western blotting analysis of different PKC isoform from hairy cell leukemia (HCL), normal B-cell and CLL cells demonstrated that PKCbII is the dominant isoform in CLL, but the expression of PKCf is also elevated (Fig. 4) . Moreover, PKCbII expression is sevenfold higher in CLL compared to that in HCL and B-cells [55] . A recent study using microarray data from patient samples showed an elevated expression of PKCbII and PKCf mRNA in CLL [21] . Differential expression of PKC isoforms in CLL patients opens for a possibility of targeting specific PKC isoforms in this disease. Although multiple PKC isoforms are found to be overexpressed in CLL, several CLL studies have pointed toward PKCbII. These studies suggest that elevated expression of PKCbII correlates with aggressive disease phenotype in CLL [56] [57] [58] . Furthermore, elevated PKCbII expression is sufficient to promote carcinogenesis [59, 60] . Therefore, targeting PKCbII might provide a novel approach in treatment for CLL.
The role of PKC isoforms in CLL
It is now widely accepted that BCR signaling is of importance for CLL pathogenesis. Mutations of BCR sequences contribute to the survival and proliferation of B-cells. The expression of the cell surface molecules CD38 further supports this process. Survival signals from the cell surface B-cell receptor are propagated through a number of signaling proteins including the non-receptor tyrosine kinases Syk, Lyn and ZAP70 [61] . Patients with clones carrying few IgV H mutations or with many CD38? or ZAP70?B-cells suffer from aggressive disease, while patients with IgV H mutated clones or few CD38? and ZAP70?B-cells have a favorable prognosis [61] . Thus, targeting BCR signaling is a potential avenue in developing CLL therapies.
Upon antigen binding BCR creates a complex with multiple proteins including SFKs and SYK. This complex activates PLCc2 through membrane-recruited Bruton tyrosine kinase (BTK) [62] . PLCc2 catalyzes the hydrolysis of PIP 2 into DAG and IP 3 . Generation of IP 3 results in increased intracellular calcium ion levels. Thus, enrichment of DAG and calcium ion triggers activation of classical PKC isoforms which further activates survival pathways through NF-jB (Fig. 5) [63] . Activation of PKCbII can phosphorylate BTK [64] . This phosphorylation inhibits membrane translocation of BTK resulting in negative regulation of BCR signaling [65] . Thus, activation of PKC not only activates pro-survival pathways, it also activates a negative feedback loop.
ZAP70 is an important regulator of T-cell receptor signaling playing equivalent role like Syk in BCR signaling. ZAP70 has also been described as a key component of BCR signaling. In BCR signaling, ZAP70 acts as an adaptor protein enhancing BCR signaling [66] [67] [68] . The exact mechanism behind this regulation was unknown until investigators observed that PKCbII is constitutively associated with lipid rafts in ZAP70-positive CLL cells [23] . Since ZAP70 is constitutively associated with lipid rafts, it probably recruits PKCbII to the rafts. This recruitment enhances PKCbII activation and activated PKCbII translocates to the mitochondria where it associates with and phosphorylates the anti-apoptotic protein BCL2 and the pro-apoptotic protein BIM EL [23] . While phosphorylation of BIM EL directs this protein for proteasomal degradation, BCL2 phosphorylation enhances this process. Therefore, PKCbII-mediated anti-apoptotic effects in CLL [69] are mediated through early activation of NF-jB pathway as well as downregulation of BIM EL .
PKC inhibitors in CLL
Treatment for CLL generally involves combination chemotherapies which generate severe side effects. Targeted therapy allows more specific treatment option. This approach appears to be more popular but still suffers from moderate response and secondary resistance to the drugs. Recent studies suggest that mutations in the inhibitor binding pocket confer secondary resistance [70] . Thus, robust drug targets are required for better treatment outcome. Specific signaling molecules are important players of malignant transformation and promising targets for cancer treatment. Multiple small molecule PKC inhibitors have been used in clinical trials including staurosporine, enzastaurin, aprinocarsen, midostaurin, UCN-01 and bryostatin 1 with disappointing results (For review see [71] ). Besides these synthetic molecules, short polypeptide sequence for different PKC isoforms exhibited promising results in animal models [71] . Although most small molecule inhibitors lack specificity for the different isoforms of PKC and inhibit a wide range of kinases, short polypeptides are highly specific inhibitors.
Since PKC isoforms are specifically overexpressed in many cancers including CLL, targeted therapy against specific isoforms could be beneficial. The non-specific PKC inhibitor midostaurin (PKC 412) inhibits growth of B-cell chronic lymphocytic leukemia (B-CLL) in vitro [72] . Treatment for CLL cells with the PKC inhibitor UCN-01 efficiently abrogates cell growth [73] . Both UNC-01 and midostaurin induce cell death independent of p53 or IgV H mutational status [72, 73] . Since these drugs are non-specific, PKC inhibitors effects might not be exclusive mediated by PKC inhibition. Furthermore, PKC-induced B-CLL cell survival can be inhibited by BisI [74] . BisI induces apoptosis by blocking PKC activation and accelerates dexamethasoneand fludarabine-induced apoptosis in the presence of survival factors. The PKC inhibitor safingol controls growth of CLL by inducing apoptosis [54] . Although a PKCa antisense oligonucleotide, aprinocarsen, has been used in preclinical and clinical studies [75] , patients with CLL would not benefit from this therapy since PKCa expression has been found to be downregulated in this disease [21] . These studies suggest that PKC inhibitors are capable of CLL growth control by inducing apoptosis. The PKCbII inhibitor enzastaurin effectively kills CLL cells and enhances toxicity of chemotherapy [23] , and the specific inhibitor against PKCd induces apoptosis of CLL cells even in presence of survival factors [24, 76] . These findings further suggest that targeted therapy against PKC isoforms might be a valuable approach for CLL treatment. Thus, involvement of PKC isoforms in CLL pathogenesis is proven, and the simultaneous administration of PKC inhibitor with other drugs has the potential to be beneficial for CLL patients.
Conclusion
Recent studies have established that several PKC isoforms are overexpressed in CLL and are essential for CLL cell survival [21, 52, 54, 55, 77] . Clinical trials using the PKC inhibitors PKC412 and enzastaurin have provided promising results with low side effects in CLL treatment [78] [79] [80] . Therefore, inhibition of distinct PKC isoforms may offer an important contribution to the targeted therapy of CLL.
